Skip to main content

Advertisement

Table 1 Characteristics of Extension enrollees and nonparticipants at FREEDOM baseline

From: Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study

  Placebo (N = 3906) Denosumab (N = 3902) Combined (N = 7808)
Extension nonparticipants (N = 1699) Extension enrollees (N = 2207) Extension nonparticipants (N = 1559) Extension enrollees (N = 2343) Extension nonparticipants (N = 3258) Extension enrollees (N = 4550)
Age, years
 Mean (SD) 73.1 (5.3) 71.8 (5.1)a 73.0 (5.4) 71.9 (5.0)a,b 73.1 (5.4) 71.8 (5.0)
 Median (range) 73 (60–91) 72 (60–90) 73 (60–89) 72 (60–90) 73 (60–91) 72 (60–90)
Age group, n (%)
  ≥ 70 years 1307 (77) 1571 (71) 1200 (77) 1672 (71) 2507 (77) 3243 (71)
  ≥ 75 years 612 (36) 624 (28)a 573 (37) 662 (28)a,b 1185 (36) 1286 (28)
  ≥ 80 years 203 (12) 143 (6) 178 (11) 144 (6) 381 (12) 287 (6)
Prior fracture, n (%)
 Prior vertebral 430 (25) 485 (23)a 370 (24) 559 (24)a,b 800 (25) 1044 (23)
 Prior nonvertebralc 526 (31) 651 (29) 461 (30) 702 (30)b 987 (30) 1353 (30)
BMD T-score, mean (SD)
 Lumbar spine –2.8 (0.7) –2.8 (0.7)a –2.8 (0.7) –2.8 (0.7)a,b –2.8 (0.7) –2.8 (0.7)
 Total hip –2.0 (0.8) –1.9 (0.8)a –1.9 (0.8) –1.9 (0.8)a,b –2.0 (0.8) –1.9 (0.8)
FRAX® probability,d %, mean (SD)
 Hip 7.4 (7.7) 6.6 (7.3) 7.5 (8.0) 6.8 (7.2) 7.4 (7.8) 6.7 (7.3)
 Major osteoporotic 17.8 (9.8) 16.8 (9.7) 17.6 (9.9) 17.0 (9.6) 17.7 (9.8) 16.9 (9.6)
  1. BMD bone mineral density, FRAX ® Fracture Risk Assessment Tool, SD standard deviation
  2. aPublished in Papapoulos et al, 2012 [2]
  3. bPublished in Ferrari et al, 2015 [5]
  4. cAt age ≥ 55 years
  5. d10-year probability of fracture calculated with femoral neck BMD